Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen.

Since 1990, the Developmental Therapeutics Program (DTP) of the National Cancer Institute (NCI) has screened over 60 000 compounds and a larger number of natural product extracts for their capacity to inhibit the growth of 60 different human tumor cell lines (1). These cell lines have been maintained in cryopreservation and in culture, and they have been subjected to strict quality controls, including adventitious agent testing, human isoenzyme analysis, karyology, morphological and immunocytochemical characterization (2), and DNA fingerprinting. One of these cell lines, previously designated as MCF-7/ADR-RES, has been included in the in vitro cell line screening panel because of its stable multidrug-resistant (MDR) phenotype(3) characterized by high levels of MDR-1 and Pglycoprotein expression (4,5).Recently, we submitted cell lines from the screening panel for DNA fingerprinting analysis by three different laboratories. Included in the tested cell lines were MCF-7 and MCF-7/ADR-RES. Utilizing restriction fragment length polymorphism (RFLP) testing, CellMark Diagnostics (Germantown, MD) concluded that their DNA fingerprinting data were consistent with each of the cell lines (MCF-7 and MCF-7/ADR-RES) having different donors. The other laboratories—American Type Culture Collection (Rockville, MD) used both RFLP and amplification fragment length polymorphism (AmpFLP) methods, and Children’s Hospital of Michigan Cell Culture Laboratory (Detroit, MI) used the AmpFLP method—reached the same conclusions. Based on the reports from these DNA fingerprinting analyses, we have concluded that the preponderance of the information available suggests that the MCF-7/ADR-RES multidrug-resistant cell line that is included in the DTP screening program is not related to the MCF-7 cell line that is a part of the screening panel. Thus, we have changed the nomenclature of the MCF-7/ADR-RES multidrug-resistant cell line. The new designation of this cell line is NCI/ADR-RES. This nomenclature change will soon appear in all DTP databases, including the worldwide web. The DTP web site address is: http:// epnws1.ncifcrf.gov:2345/dis3d/dtp.html Irrespective of its origin, this cell line has served as a valuable sentinel for compounds interacting with the multidrug-resistant mechanism (5).

[1]  L. Boros,et al.  Expression of somatostatin receptor subtype 1-5 genes in human pancreatic cancer. , 1998, Journal of the National Cancer Institute.

[2]  S. Barnes,et al.  Phyto-oestrogens and breast cancer , 1997, The Lancet.

[3]  D. Ingram,et al.  Case-control study of phyto-oestrogens and breast cancer , 1997, The Lancet.

[4]  Chun-Fang Xu,et al.  Complex Regulation of the BRCA1 Gene* , 1997, The Journal of Biological Chemistry.

[5]  N. Vaysse,et al.  sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. , 1997, Cancer research.

[6]  G. Capellá,et al.  Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. , 1996, Cancer research.

[7]  H. Nguyen,et al.  Hormone-dependent regulation of BRCA1 in human breast cancer cells. , 1995, Cancer research.

[8]  M. Grever,et al.  Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. , 1995, The Journal of clinical investigation.

[9]  David L. Page,et al.  Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression , 1995, Nature Genetics.

[10]  G. Bell,et al.  Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[12]  M. Grever,et al.  Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. , 1994, Molecular pharmacology.

[13]  M. Boyd,et al.  Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. , 1992, Anticancer research.

[14]  L V Rubinstein,et al.  Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. , 1992, Cancer research.

[15]  D. Scudiero,et al.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. , 1991, Journal of the National Cancer Institute.

[16]  A. Schally,et al.  Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. , 1989, Proceedings of the National Academy of Sciences of the United States of America.